Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Vismodegib |
Trade Name | Erivedge |
Synonyms | GDC-0449 |
Drug Descriptions |
Erivedge (vismodegib) binds to and inhibits Smoothened (SMO), resulting in inhibition of downstream signaling and decreased tumor growth (PMID: 24259609, PMID: 19716296). Erivedge (vismodegib) is FDA approved for use in patients with basal cell carcinoma (FDA.gov). |
DrugClasses | SMO Inhibitor 16 |
CAS Registry Number | 879085-55-9 |
NCIT ID | C74038 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cytarabine + Vismodegib | Cytarabine Vismodegib | 0 | 1 |
Gemcitabine + Nab-paclitaxel + Vismodegib | Gemcitabine Nab-paclitaxel Vismodegib | 0 | 1 |
Pembrolizumab + Vismodegib | Pembrolizumab Vismodegib | 0 | 1 |
Posaconazole + Vismodegib | Posaconazole Vismodegib | 0 | 0 |
Ribavirin + Vismodegib | Ribavirin Vismodegib | 0 | 1 |
RO4929097 + Vismodegib | RO4929097 Vismodegib | 0 | 1 |
Sirolimus + Vismodegib | Sirolimus Vismodegib | 0 | 1 |
Vismodegib | Vismodegib | 54 | 19 |